CareDx stockholders approve 1.6M share increase to 2024 Equity Incentive Plan

Proposal 2: Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. Shares For Shares Against Shares Abstaining Broker Non-Votes 48,012,497 111,586 18,649 — The Company’s stockholders ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2026.

Proposal 5: Approval of the amendment of the Company’s 2024 Equity Incentive Plan. Shares For Shares Against Shares Abstaining Broker Non-Votes 27,575,633 13,702,645 34,744 6,829,710 The Company’s stockholders voted to approve the Plan Amendment.

Proposal 3: Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers. Shares For Shares Against Shares Abstaining Broker Non-Votes 39,387,247 1,905,070 20,705 6,829,710 The Company’s stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers.

Proposal 4: Approval, on a non-binding advisory basis, of the frequency of advisory votes on the compensation of the Company’s named executive officers. One Year Two Years Three Years Abstaining Broker Non-Votes 39,804,235 64,263 1,416,678 27,846 6,829,710 The Company’s stockholders advised that they were in favor of “one year” as the frequency of holding future advisory votes on the compensation of the Company’s named executive officers. Based on the results of the advisory vote, the Company’s Board of Directors has determined that the Company will hold an advisory vote on the compensation of its named executive officers every one year.

Proposal 1: Election of three Class II directors and two Class III directors, identified in the table below, each to serve a one-year term, which will expire at the 2027 Annual Meeting of Stockholders and until such time as their respective successors have been duly elected and qualified or until their earlier death, resignation or removal. Nominees Class Shares For Shares Withheld Broker Non-Votes Fred E. Cohen, M.D., D. Phil II 40,271,984 1,041,038 6,829,710 R. Bryan Riggsbee II 38,851,207 2,461,815 6,829,710 Suresh Gunasekaran II 41,091,649 221,373 6,829,710 Michael D. Goldberg III 38,837,463 2,475,559 6,829,710 John W. Hanna III 40,812,915 500,107 6,829,710 Each of the five nominees for director was elected to serve until the Company’s 2027 annual meeting of stockholders and until such director’s successor has been duly elected and qualified, or until such director’s earlier death, resignation or removal.